Pacylex

Pacylex Presented Initial Clinical Experience with PCLX-001 in Patients at ASH 2021

Pacylex today announced that data from the first ever clinical trial of an N-myristoyltransferase (NMT) inhibitor was presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. This update included the design of the first clinical trial with PCLX-001 in Non-Hodgkin’s Lymphoma and solid tumor patients and an update on the first dose cohort.

Read the full press release here: Pacylex ASH Annual Meeting Poster.

December 13, 2021